Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale

Rhea-AI Filing Summary

OCULAR THERAPEUTIX, INC. (OCUL) received a Notice of Proposed Sale of Securities on Form 144 filed for officer Pravin Dugel. The notice covers a proposed sale of 21,649 shares of common stock, relating to restricted stock scheduled to vest on August 22, 2026, to be sold through Morgan Stanley Smith Barney LLC. The filing also reports that Dugel sold 21,156 shares of common stock during the prior three months for aggregate proceeds of $173,513.05.

Key Figures

Proposed shares to be sold: 21,649 shares of common stock Approximate aggregate market value of proposed sale: $233,185.71 Shares sold in past 3 months: 21,156 shares of common stock +1 more

4 metrics

Proposed shares to be sold 21,649 shares of common stock Planned sale under Form 144 related to restricted stock vesting on August 22, 2026

Approximate aggregate market value of proposed sale $233,185.71 Value associated with the 21,649 OCUL common shares listed in the Form 144

Shares sold in past 3 months 21,156 shares of common stock Sale on May 26, 2026 by Pravin Dugel reported in the Form 144

Aggregate proceeds from past 3-month sale $173,513.05 Total proceeds from 21,156 OCUL shares sold on May 26, 2026

Key Terms

Form 144, restricted stock vesting, registered plan, Rule 144

4 terms

Form 144 regulatory

"Notice of Proposed Sale of Securities on Form 144 filed for officer"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted stock vesting financial

"Restricted Stock Vesting Under a Registered Plan on August 22, 2026"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

registered plan financial

"Restricted Stock Vesting Under a Registered Plan"

A registered plan is a savings or investment account that a government recognizes for special tax treatment and rules, such as limits on how much you can put in and conditions for withdrawals. For investors it matters because those rules change how much of your gains are taxed, how quickly your money can be accessed and what strategies make sense — like a labeled jar that gives tax breaks but comes with rules about when and how you can take the money out.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

What does the Form 144 filing disclose for OCUL insider Pravin Dugel?

The Form 144 discloses that officer Pravin Dugel plans a potential sale of 21,649 OCUL common shares related to restricted stock vesting on August 22, 2026, and that he has sold 21,156 shares in the past three months for $173,513.05.

How many OCUL shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 21,649 shares of OCULAR THERAPEUTIX, INC. common stock, tied to restricted stock vesting under a registered plan on August 22, 2026, with Morgan Stanley Smith Barney LLC listed as the broker.

What OCUL stock sales has Pravin Dugel made in the last three months?

In the prior three months, Pravin Dugel reported selling 21,156 OCUL common shares on May 26, 2026 for total proceeds of $173,513.05, according to the sales history section of the Form 144.

Who is the broker for the proposed OCUL share sale on this Form 144?

The proposed sale of 21,649 OCUL common shares is indicated to be through Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, as listed in the securities information section of the Form 144.

What is the nature of the OCUL securities to be sold under this Form 144?

The securities are common stock of OCULAR THERAPEUTIX, INC. arising from restricted stock vesting under a registered plan on August 22, 2026, with the issuer identified as the source of those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:45 PM Accepted by SEC EDGAR 08/24/2026 - 04:45 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001700917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	14 CROSBY DRIVE, 3RD FLOOR BEDFORD MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	PRAVIN DUGEL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21649	233185.71	219615868	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2026	Restricted Stock Vesting Under a Registered Plan	Issuer			21649	08/22/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PRAVIN DUGEL 15 Crosby Drive Bedford MA 01730	Common	05/26/2026	21156	173513.05

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Pravin Dugel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)